Overview

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Status:
RECRUITING
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed (RALOX-HAIC) versus DEB-TACE alone for unresectable large hepatocellular carcinoma (HCC).
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Collaborators:
Guangzhou Development District Hospital
The Affiliated Shunde Hospital of Jinan University
Zhongshan People's Hospital, Guangdong, China